Goldman Sachs
DMTX

Goldman Sachs’s Dimension Therapeutics, Inc DMTX Stock Holding History

Goldman Sachs’s Portfolio DMTX Stock Details DMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-80,471
Closed -$117K – 7153
2017
Q2 		$117K Buy
80,471
+54,231
+207% +$73.7K ﹤0.01% 6059
2017
Q1 		$46K Buy
26,240
+6,390
+32% +$16.9K ﹤0.01% 6314
2016
Q4 		$86K Sell
19,850
-1,049
-5% -$5.58K ﹤0.01% 6209
2016
Q3 		$167K Sell
20,899
-75,823
-78% -$548K ﹤0.01% 5944
2016
Q2 		$580K Buy
+96,722
New +$736K ﹤0.01% 4717
2016
Q1 		– Sell
-108,945
Closed -$1.23M – 7687
2015
Q4 		$1.23M Buy
+108,945
New +$1.38M ﹤0.01% 4093

Other funds holding DMTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $507M AUM 6.15% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Goldman Sachs's DMTX Position: Q3 2017 in Review

Goldman Sachs sold out of Dimension Therapeutics, Inc (DMTX) in Q3 2017, closing a stake of 80,471 shares — an estimated $117K sold.

Goldman Sachs first reported a position in DMTX in Q4 2015 and held it in 6 quarters. The position peaked at $1.23M in Q4 2015. 34 funds tracked by Wall St. Rank hold DMTX as of Q3 2017.

  • Goldman Sachs reported no remaining Dimension Therapeutics, Inc position as of Q3 2017 after selling out during the quarter.
  • Goldman Sachs sold 80,471 Dimension Therapeutics, Inc shares in Q3 2017, an estimated $117K.
  • Goldman Sachs first reported a position in Dimension Therapeutics, Inc in Q4 2015 and held it in 6 quarters.
  • Goldman Sachs's Dimension Therapeutics, Inc position peaked at $1.23M in Q4 2015.
  • 34 funds tracked by Wall St. Rank held Dimension Therapeutics, Inc as of Q3 2017.

Based on Goldman Sachs's 13F filing for Q3 2017, filed 14 Nov 2017.